Eitan Amir, Ph.D.
Affiliations: | 2012 | Health Policy, Management and Evaluation | University of Toronto, Toronto, ON, Canada |
Area:
Health Care Management, OncologyGoogle:
"Eitan Amir"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Ian F. Tannock | grad student | 2012 | University of Toronto | |
| (Optimizing the Tailored Treatment of Breast Cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kappel C, Elliott MJ, Kumar V, et al. (2024) Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer. Scientific Reports. 14: 3129 |
| Mittal A, Tamimi F, Molto C, et al. (2024) Benefit of adjuvant bisphosphonates in early breast cancer treated with contemporary systemic therapy: A meta-analysis of randomized control trials. Heliyon. 10: e24793 |
| Shachar SS, Korzets Y, Shepshelovich D, et al. (2023) Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review. Cancer Treatment Reviews. 122: 102666 |
| Molto Valiente C, Amir E. (2023) Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer. Translational Cancer Research. 12: 1887-1890 |
| Mittal A, Tamimi F, Molto C, et al. (2022) Three-year Disease-free Survival in Randomized Trials of Neoadjuvant Chemotherapy and HER2-targeted therapy in Breast Cancer: A meta-analysis. Critical Reviews in Oncology/Hematology. 103880 |
| Saleh RR, Nadler MB, Desnoyers A, et al. (2021) Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis. Cancer Treatment Reviews. 100: 102283 |
| Ethier JL, Desautels D, Robinson A, et al. (2021) Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer. Jama Oncology |
| Desnoyers A, Amir E, Tannock IF. (2021) Adjuvant Zoledronate Therapy for Women With Breast Cancer-Effective Treatment or Fool's Gold? Jama Oncology |
| Reinhorn D, Mutai R, Yerushalmi R, et al. (2021) Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis. Breast (Edinburgh, Scotland). 58: 173-181 |
| Ethier JL, Anderson GM, Austin PC, et al. (2021) Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. European Journal of Cancer (Oxford, England : 1990). 149: 117-127 |